Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib — DASCERN

Chronic Phase Chronic Myeloid Leukemia Clinical Trial

Official title:
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Status Completed

Clinical Trial Summary

The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying on their original imatinib regimen.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Phase Chronic Myeloid Leukemia
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase

Clinical Trial Details

NCT number	NCT01593254
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 2
Start date	September 12, 2012
Completion date	April 12, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03610971` - Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors	Phase 2
Completed	`NCT03045120` - Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Recruiting	`NCT03934372` - Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	Phase 1/Phase 2
Completed	`NCT01850004` - Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response	Phase 2
Completed	`NCT01702064` - Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients	Phase 1
Terminated	`NCT02627677` - A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia	Phase 3
Completed	`NCT01660906` - Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib	Phase 4
Completed	`NCT01933906` - Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response	Phase 1
Completed	`NCT01914484` - Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia	Phase 1/Phase 2